OND2

About this trial

Last updated 14 years ago

Study ID

OND2

Status

Completed

Type

Interventional

Phase

Phase 4

Placebo

Accepting

18 to 60 Years

All

Not accepting

Healthy Volunteers

Trial Timing

Ended 15 years ago

The aim of this study is to evaluate whether ondansetron augmentation to SSRI will improve and ondansetron discontinuation will result in worsening of obsessive compulsive symptoms among obsessive compulsive disorder resistant patients.

Inclusion Criteria

- a diagnosis of OCD established by clinical interview with a licensed psychiatrist;

- a score of ≥ 24 at the Yale Brown Obsessive Compulsive Scale

- a Clinical Global Inventory score ≥ 4, after over 12 weeks of treatment with an adequate trial of an selective serotonin reuptake inhibitor at a moderate to high dose

Exclusion Criteria

- diagnoses of schizophrenia, schizoaffective disorder, organic mental disorder, bipolar disorder, current substance dependence or abuse, and current major depressive episode preceding the onset of obsessive compulsive disorder

- undergoing concomitant behavior therapy

- or having significant cardiovascular, hepatic, renal or pulmonary diseases

Ondansetron Augmentation in Treatment-resistant OCD